GlassScriptPhysician profile
Kenneth L Bain
NPI 1063470714
$6,770.59
in general payments reported to CMS, 2019-2025
42 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2020: $1,140 · 2021: $1,250 · 2022: $1,056 · 2023: $815 · 2024: $794 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,037.31 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Abbvie INC. | $1,023.44 | 2021-2025 | Vraylar, Ubrelvy |
| Janssen Pharmaceuticals, INC | $719.08 | 2019-2022 | |
| Novo Nordisk INC | $456.75 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $417.67 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $416.06 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $409.88 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Genzyme Corporation | $350.00 | 2019-2020 | |
| Astellas Pharma US INC | $198.42 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $173.73 | 2021-2023 | Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.98 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $163.45 | 2019-2022 | |
| Allergan, INC. | $152.07 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.28 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.25 | 2021-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Bain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.